A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have been diagnosed with type 2 diabetes mellitus (T2DM)
Are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older.
Have HbA1c at screening
* ≥7.0% and ≤10.5% if background diabetes medication does not include a sulfonylurea, or
* ≥7.5% and ≤10.5% if background diabetes medication includes a sulfonylurea.
Are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. Antihyperglycemic drugs may include metformin, SGLT-2 inhibitors, and/or sulfonylureas
Have increased risk for cardiovascular (CV) events due to:
* Coronary heart disease
* Peripheral arterial disease, presumed to be of atherosclerotic origin
* Cerebrovascular disease, presumed to be of atherosclerotic origin
* Chronic kidney disease (CKD)
* Congestive heart failure (CHF) New York Heart Association (NYHA) functional classification II to III
Are of stable weight (± 5%) for at least 90 days prior to screening
Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening
You may not be if
Have type 1 diabetes mellitus
Have had chronic or acute pancreatitis any time prior to screening
Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (e.g. laster photocoagulation or intravitreal injections of anty-VEGF inhibitors
Have a known clinically significant gastric emptying abnormality
Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) or aspartate aminotransferase (AST) enzyme level ≥5.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory
Have had any of the following within 60 days prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization for congestive heart failure
Have an eGFR \<15 mL/min/1.73 m2 as determined at screening
Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Have been taking any other diabetes medicines other than metformin, SGLT-2 inhibitors, and/or sulfonylureas during the last 90 days
Have used any weight loss drugs, including herbal or nutritional supplements, within 90 days of screening
Clareo Health | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
